DIGITEK

On April 25, 2008, Actavis Totowa, LLC, the United States manufacturing division of the generic pharmaceutical company Actavis Group, voluntarily initiated a Class 1 nationwide recall of Digitek oral tablets of all strengths. Digitek is distributed by Mylan Pharmaceuticals, Inc. under a "Bertek" label and by UDL Laboratories, Inc. under a "UDL" label. Digitek (digoxin) is the #1 choice for treating congestive heart failure and abnormal heart rhythms in the United States.

The voluntary recall of the Digitek tablets manufactured at the New Jersey Actavis facility occurred because tablets may have been commercially released in the United States market with double the thickness of the normal sized tablets. The improperly manufactured Digitek tablets may contain as much as twice the active ingredient, meaning they have twice the strength of the recommended dosage. A double-strength tablet could cause serious digitalis toxicity resulting in nausea, vomiting, dizziness, low blood sugar, cardiac instability, bradycardia, and even death. In fact, Actavis Totowa has received numerous reports of illnesses and injuries due to patients who may have taken the double-strength tablets.

Digitek is the only drug containing digoxin that was recalled from the United States market. (Other digoxin brand names include Lanoxin, Lanoxicaps, and Cardoxin are not part of this litigation.)

If you think you or a loved one may have suffered an illness following taking Digitek double-strength oral tablets, you should speak with an attorney to see if you have a case and to discuss the possibility of bringing a lawsuit for money damages. Your attorneys may determine if you have a claim for which a lawsuit may be pursued. Please contact the law firm of Ury & Moskow, L.L.C. to discuss your potential claim with an experienced pharmaceutical lawyer.